Clinical trial

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

NCT02432963

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2016-06-14

PhasePHASE1

Study timeline

Study start (actual)2016-06-14Date precision: day

Registry last updated2026-01-28

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Adult Solid Neoplasmunresolved

Bladder Carcinomaunresolved

Colon Carcinomaunresolved

Estrogen Receptor Negativeunresolved

Head and Neck Squamous Cell Carcinomaunresolved

Hepatocellular Carcinomaunresolved

HER2/Neu Negativeunresolved

Melanomaunresolved

Non-Small Cell Lung Carcinomaunresolved

Pancreatic Carcinomaunresolved

Progesterone Receptor Negativeunresolved

Rectal Carcinomaunresolved

Renal Cell Carcinomaunresolved

Soft Tissue Sarcomaunresolved

Triple-Negative Breast Carcinomaunresolved

TP53 Gene Mutationunresolved

Unresectable Solid Neoplasmunresolved

Interventions

Laboratory Biomarker AnalysisOTHER

Modified Vaccinia Virus Ankara Vaccine Expressing p53BIOLOGICAL

PembrolizumabBIOLOGICAL

Sponsors & collaborators

City of Hope Medical Centerlead sponsor

National Cancer Institute (NCI)collaborator

Mapped research locations

DuarteCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02432963 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.